Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy

References

• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell. 1999;98:295–16. doi:10.1016/S0092-8674(00)81959-5.
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474–2488. doi:10.1038/sj.onc.1203527.
   PubMed Web of Science ®Google Scholar
• Proietti CJ, Izzo F, Diaz Flaque MC, Cordo RR, Venturutti L, Mercogliano MF, De Martino M, Pineda V, Munoz S, Guzman P, et al. Heregulin co-opts PR transcriptional action via Stat3 role as a coregulator to drive cancer growth. Mol Endocrinol. 2015;29:1468–1485. doi:10.1210/me.2015-1170.
   PubMedGoogle Scholar
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54. doi:10.1038/nm976.
   PubMed Web of Science ®Google Scholar
• Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123:1580–1589. doi:10.1172/JCI60083.
   PubMed Web of Science ®Google Scholar
• Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Muller M, Sexl V. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014;124:2370–2379. doi:10.1182/blood-2014-03-564450.
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41–51. doi:10.1038/nri1995.
   PubMed Web of Science ®Google Scholar
• Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Diaz Flaque MC, Beguelin W, Frahm I, Charreau EH, Cassataro J, et al. Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. J Immunol. 2012;189:1162–1172. doi:10.4049/jimmunol.1102538.
   PubMed Web of Science ®Google Scholar
• Johnson LM, Price DK, Figg WD. Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. Cancer Biol Ther. 2013;14:90–91. doi:10.4161/cbt.22636.
   PubMed Web of Science ®Google Scholar
• Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, Gewirtz DA. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol. 2005;81:445–458. doi:10.1080/09553000500168549.
   PubMed Web of Science ®Google Scholar
• Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593–602. doi:10.1016/S0092-8674(00)81902-9.
   PubMed Web of Science ®Google Scholar
• Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614–636. doi:10.1016/0014-4827(65)90211-9.
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes–the achilles heal of cancer. Science. 2002;297:63–64. doi:10.1126/science.1073096.
   PubMed Web of Science ®Google Scholar
• Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199–207. doi:10.1016/S1097-2765(00)80367-6.
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656–660. doi:10.1038/nature05529.
   PubMed Web of Science ®Google Scholar
• Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547–551. doi:10.1038/nature10599.
   PubMed Web of Science ®Google Scholar
• Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, et al. TNFalpha-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res. 2017;23:636–648. doi:10.1158/1078-0432.CCR-16-0970.
   PubMed Web of Science ®Google Scholar
• Kumamoto T, Huang EK, Paek HJ, Morita A, Matsue H, Valentini RF, Takashima A. Induction of tumor-specific protective immunity by in situ langerhans cell vaccine. Nat Biotechnol. 2002;20:64–69. doi:10.1038/nbt0102-64.
   PubMed Web of Science ®Google Scholar
• Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–362. doi:10.1038/nmeth.1322.
   PubMed Web of Science ®Google Scholar
• Poullet P, Carpentier S, Barillot E. myProMS, a web server for management and validation of mass spectrometry-based proteomic data. Proteomics. 2007;7:2553–2556. doi:10.1002/pmic.200600784.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–284. doi:10.1016/s0166-4328(01)00297-2.
   PubMed Web of Science ®Google Scholar
• Vizcaino JA, Csordas A, Del Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:11033. doi:10.1093/nar/gkv1145.
   PubMed Web of Science ®Google Scholar
• Feizi A, Banaei-Esfahani A, Nielsen J. HCSD: the human cancer secretome database. Database. 2015. doi:10.1093/database/bav051.
   PubMedGoogle Scholar
• Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113–1120. doi:10.1038/ng.2764.
   PubMed Web of Science ®Google Scholar
• Wei L, Jin Z, Yang S, Xu Y, Y Z, Ji Y. TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data. Bioinformatics. 2018;34:1615–1617. doi:10.1093/bioinformatics/btx812.
   PubMed Web of Science ®Google Scholar
• R: A Language and Environment for Statistical Computing. R Core Team organization = R Foundation for Statistical Computing. Vienna, Austria; 2018. https://www.R-project.org/
   Google Scholar
• Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55–62. doi:10.1038/nature18003.
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–1167. doi:10.1200/JCO.2008.18.1370.
   PubMed Web of Science ®Google Scholar
• Fresno C, Gonzalez GA, Merino GA, Flesia AG, Podhjacer OL, Llera AS, Fernández E. A novel non-parametric method for uncertainty evaluation of correlation-based molecular signatures: its application on PAM50 algorithm. Bioinformatics. 2017;33:693–700. doi:10.1093/bioinformatics/btw704.
   PubMed Web of Science ®Google Scholar
• Xin J, Mark A, Afrasiabi C, Tsueng G, Juchler M, Gopal N, Stupp GS, Putman TE, Ainscough BJ, Griffith OL, et al. High-performance web services for querying gene and variant annotation. Genome Biol. 2016;17(1):1–7. doi:10.1186/s13059-016-0953-9.
   PubMedGoogle Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363–9367. doi:10.1073/pnas.92.20.9363.
   PubMed Web of Science ®Google Scholar
• Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703–716. doi:10.1016/S0092-8674(03)00401-X.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al Regaiey K, Su L, Sharpless NE. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114:1299–1307. doi:10.1172/JCI22475.
   PubMed Web of Science ®Google Scholar
• Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102–104. doi:10.1126/science.1071489.
   PubMed Web of Science ®Google Scholar
• Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, et al. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018;32:49–60. doi:10.1038/leu.2017.174.
   PubMed Web of Science ®Google Scholar
• Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs. JAKSTAT. 2013;2:e23820. doi:10.4161/jkst.23820.
   PubMedGoogle Scholar
• Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. 2010;16:238–246. doi:10.1016/j.molmed.2010.03.003.
   PubMed Web of Science ®Google Scholar
• Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M. Unmasking transcriptional heterogeneity in senescent cells. Curr Biol. 2017;27:2652–2660. doi:10.1016/j.cub.2017.07.033.
   PubMed Web of Science ®Google Scholar
• Uthus EO, Brown-Borg HM. Altered methionine metabolism in long living Ames dwarf mice. Exp Gerontol. 2003;38:491–498. doi:10.1016/S0531-5565(03)00008-1.
   PubMed Web of Science ®Google Scholar
• Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem. 2007;100:1337–1345. doi:10.1002/jcb.21194.
   PubMed Web of Science ®Google Scholar
• de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69:912–920. doi:10.1189/jlb.69.6.912.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for cellular senescence. Proc Natl Acad Sci U S A. 2017;114:E4612–E4620. doi:10.1073/pnas.1705499114.
   PubMed Web of Science ®Google Scholar
• Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, Simithy J, Lan Y, Lin Y, Zhou Z, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017;550:402–406. doi:10.1038/nature24050.
   PubMed Web of Science ®Google Scholar
• Gluck S, Guey B, Gulen MF, Wolter K, Kang TW, Schmacke NA, Bridgeman A, Rehwinkel J, Zender L, Ablasser A. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol. 2017;19:1061–1070. doi:10.1038/ncb3586.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S. SnapShot: CGAS-STING Signaling. Cell. 2018;173:276. doi:10.1016/j.cell.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic DNA sensing in organismal tumor control. Cancer Cell. 2018;34:361–378. doi:10.1016/j.ccell.2018.05.013.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–2868. doi:10.1371/journal.pbio.0060301.
   PubMed Web of Science ®Google Scholar
• Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010;18:485–498. doi:10.1016/j.ccr.2010.10.002.
   PubMed Web of Science ®Google Scholar
• Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 2007;67:3117–3126. doi:10.1158/0008-5472.CAN-06-3452.
   PubMed Web of Science ®Google Scholar
• Zacarias-Fluck MF, Morancho B, Vicario R, Luque GA, Escorihuela M, Villanueva J, Rubio IT, Arribas J. Effect of cellular senescence on the growth of HER2-positive breast cancers. J Natl Cancer Inst. 2015:107. doi:10.1093/jnci/djv020.
   PubMedGoogle Scholar
• Ewald JA, Desotelle JA, Wilding G, DF J. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102:1536–1546. doi:10.1093/jnci/djq364.
   PubMed Web of Science ®Google Scholar
• Demaria M, O’Leary MN, Chang J, Shao L, Liu S, Alimirah F, Koenig K, Le C, Mitin N, Deal AM, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165–176. doi:10.1158/2159-8290.CD-16-0241.
   PubMed Web of Science ®Google Scholar
• Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, et al. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget. 2013;4:2212–2224. doi:10.18632/oncotarget.1143.
   PubMedGoogle Scholar
• Yu YC, Yang PM, Chuah QY, Huang YH, Peng CW, Lee YJ, Chiu SJ. Radiation-induced senescence in securin-deficient cancer cells promotes cell invasion involving the IL-6/STAT3 and PDGF-BB/PDGFR pathways. Sci Rep. 2013;3:1675. doi:10.1038/srep01675.
   PubMed Web of Science ®Google Scholar
• Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 2014;9:75–89. doi:10.1016/j.celrep.2014.08.044.
   PubMed Web of Science ®Google Scholar
• Dahbour S, Jamali F, Alhattab D, Al Radaideh A, Ababneh O, Al Ryalat N, Al Bdour M, Hourani B, Msallam M, Rasheed M, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther. 2017;23:866–874. doi:10.1111/cns.12759.
   PubMed Web of Science ®Google Scholar
• Wang X, Li T, Cheng Y, Wang P, Yuan W, Liu Q, Yang F, Liu Q, Ma D, Ding S, et al. CYTL1 inhibits tumor metastasis with decreasing STAT3 phosphorylation. Oncoimmunology. 2019;8:e1577126. doi:10.1080/2162402X.2019.1577126.
   PubMed Web of Science ®Google Scholar
• Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. Cancer Res. 2015;75:3812–3822. doi:10.1158/0008-5472.CAN-15-1122.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–856. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61:1019–1031. doi:10.1007/s00262-011-1172-6.
   PubMed Web of Science ®Google Scholar